More about

Drug-Eluting Stent

News
November 16, 2020
3 min read
Save

Novel healing-targeted DES shows promise in 1-year data

Novel healing-targeted DES shows promise in 1-year data

A novel healing-targeted drug-eluting stent was as safe and effective as a standard durable polymer DES among adults with acute and chronic coronary disease undergoing PCI, early data from the PIONEER III trial show.

News
November 16, 2020
3 min read
Save

Aspirin monotherapy after 1-month DAPT safe, effective after PCI with polymer-free stent

Aspirin monotherapy after 1-month DAPT safe, effective after PCI with polymer-free stent

One month of dual antiplatelet therapy followed by aspirin monotherapy after PCI with a polymer-free drug-coated stent was noninferior to 6 to 12 months of DAPT after PCI with a contemporary drug-eluting stent, researchers reported.

News
November 05, 2020
2 min read
Save

DCB remains noninferior to DES at 3 years for PCI in small coronary vessels

DCB remains noninferior to DES at 3 years for PCI in small coronary vessels

At 3 years, a paclitaxel-coated balloon was noninferior to drug-eluting stents for treatment of CAD in patients with small coronary vessels, according to new data from the BASKET-SMALL 2 trial.

News
October 18, 2020
3 min read
Save

No sign of paclitaxel-related mortality risk in VOYAGER PAD cohort

No sign of paclitaxel-related mortality risk in VOYAGER PAD cohort

At 3.5 years after lower-extremity revascularization, there was no difference in mortality in the VOYAGER PAD cohort between patients with peripheral artery disease treated with paclitaxel-coated devices and those not treated with them.

News
October 17, 2020
2 min read
Save

14-day DAPT with nanocoated stent inferior to standard short-term DAPT strategy

14-day DAPT with nanocoated stent inferior to standard short-term DAPT strategy

Among patients on oral anticoagulation, those who had dual antiplatelet therapy for 14 days after PCI with a nanocoated stent had worse outcomes compared with those assigned 3-to-6-month DAPT after PCI with a drug-eluting stent.

News
October 17, 2020
2 min read
Save

ULTIMATE: IVUS-guided PCI superior to angiography guidance at 3 years

ULTIMATE: IVUS-guided PCI superior to angiography guidance at 3 years

In patients undergoing PCI with a drug-eluting stent, those whose procedures were guided by IVUS had less target vessel failure at 3 years than those whose procedures were guided by angiography, new data from the ULTIMATE trial showed.

News
October 01, 2020
1 min read
Save

FDA expands indication for DES to include patients with high bleeding risk

FDA expands indication for DES to include patients with high bleeding risk

Medtronic announced that the FDA approved an expanded indication for a drug-eluting stent to include patients with high bleeding risk who take dual antiplatelet therapy for 1 month after PCI.

News
July 16, 2020
1 min read
Save

SORT OUT IX

SORT OUT IX

BioFreedom stent (Biosensors) vs. Orsiro stent (Biotronik) in patients with atherosclerotic coronary artery lesions.

News
July 16, 2020
1 min read
Save

DESSOLVE III

DESSOLVE III

A novel ultrathin-strut biodegradable polymer sirolimus-eluting stent vs. a thin-strut permanent polymer everolimus-eluting stent.

News
May 14, 2020
4 min read
Save

Ticagrelor monotherapy reduces bleeding risk after PCI regardless of DES platform

Ticagrelor monotherapy reduces bleeding risk after PCI regardless of DES platform

Among patients who underwent PCI with a drug-eluting stent and were prescribed dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy reduced bleeding risk compared with continued DAPT regardless of DES type, according to results from the TWILIGHT-SYNERGY study.

View more